Drug Profile
Fentanyl - Alexza Pharmaceuticals
Alternative Names: AZ-003; EN 3294; Inhaled fentanyl aerosol - Alexza Pharmaceuticals; Staccato fentanylLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator Alexza Pharmaceuticals
- Class Amides; Benzene derivatives; General anaesthetics; Opioid analgesics; Piperidines; Small molecules
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for phase-I development in Pain in USA (Inhalation, Aerosol)
- 08 Sep 2022 Lee's Pharmaceutical plans a phase II trial for Pain (Inhalation) in September 2022 (NCT05531422)
- 19 Jan 2021 Phase-I development for Pain is ongoing in USA (Inhalation) (Alexza Pharmaceutical pipeline, January 2021)